LOS ANGELES, June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange...
Read More Details
Finally We wish PressBee provided you with enough information of ( URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm )
Also on site :
- Term Sheet Next: How Facebook’s former chief revenue officer is coaching the next generation of startup founders
- Popular Dunkin’ Menu Item Gets a ‘Glow-Up’ in Limited-Edition Release
- Nuclear agency head warns of radiological and chemical contamination inside Iran’s main nuclear site